Liquidia stock rises following YUTREPIA shipment news
Investing.com -- Shares of Liquidia Technologies Inc (NASDAQ:LQDA) were up 9.6% following the announcement that the company is scheduled to make its first commercial shipment of YUTREPIA™ (treprostinil) inhalation powder. This marks a significant milestone as YUTREPIA, approved by the FDA on May 23, 2025, for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD), will now be available to patients through specialty pharmacies.
The positive market response can be attributed to the rapid mobilization of Liquidia’s sales force and the company’s ability to swiftly list the product with compendia and ship to specialty pharmacies within five business days of receiving FDA approval. This swift action comes on the heels of a legal victory for Liquidia, as the U.S. District Court for the Middle District of North Carolina denied a preliminary injunction and a temporary restraining order sought by United Therapeutics (NASDAQ:UTHR) against Liquidia’s commercialization of YUTREPIA.
Dr. Roger Jeffs, CEO of Liquidia, expressed the company’s expeditious efforts to bring YUTREPIA to market, stating, “We have moved with exceptional speed to provide a new and differentiated therapeutic alternative to the marketplace. In just over one week, our sales force hit the ground running with the promotion of YUTREPIA, the product was listed with compendia, and commercial product was shipped to specialty pharmacies."
The denial of United Therapeutics’ request is a pivotal development, as it clears the path for Liquidia’s full commercial launch of YUTREPIA without the immediate threat of legal impediments. The court’s decision was partly based on the judgment that United Therapeutics is unlikely to succeed on the merits of its patent infringement claims.
Investors have reacted to these developments with optimism, reflecting confidence in Liquidia’s ability to navigate both regulatory and legal challenges, and in its potential to establish YUTREPIA as a leading treatment option for patients with PAH and PH-ILD. The stock movement today underscores the significance of timely product launch and favorable court rulings in shaping investor sentiment.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.
Don't miss out on the next big opportunity! Stay ahead of the curve with ProPicks – 6 model portfolios fueled by AI stock picks with a stellar performance this year..
In 2024 alone, ProPicks' AI identified 2 stocks that surged over 150%, 4 additional stocks that leaped over 30%, and 3 more that climbed over 25%. That's an impressive track record.
With portfolios tailored for Dow stocks, S&P stocks, Tech Stocks, and Mid Cap stocks, you can explore various wealth-building strategies.
So if LQDA is on your watchlist, it could be very wise to know whether or not it made the ProPicks lists.
